NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

NBTXR-3 for treating soft tissue sarcoma ID1050

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 <u>Company</u> Nanobiotix (NBTXR-3) <u>Patient/carer groups</u> Black Health Agency Cancer 52 Cancer Black Care Cancer Equality GIST Support UK HAWC Helen Rollason Cancer Charity 	 <u>General</u> Allied Health Professionals Federation All Wales Therapeutics and Toxicology Centre Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland
 Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Sarcoma UK South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care 	 Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee
 <u>Professional groups</u> Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Geriatrics Society British Psychosocial Oncology Society British Sarcoma Group Cancer Research UK Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons 	 <u>Possible comparator companies</u> None <u>Relevant research groups</u> Institute of Cancer Research MRC Clinical Trials Unit National Cancer Research Institute National Cancer Research Network National Institute for Health Research <u>Associated Public Health Groups</u> Public Health England Public Health Wales

Provisional matrix for the proposed technology appraisal of NBTXR-3 for treating soft tissue sarcoma ID1050 Issue date: November 2017

Consultees	Commentators (no right to submit or appeal)
 Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Health Forum UK Oncology Nursing Society 	
<u>Others</u>	
Department of Health	
NHS England	
 NHS North Durham CCG 	
NHS Stockport CCG	
Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Provisional matrix for the proposed technology appraisal of NBTXR-3 for treating soft tissue sarcoma ID1050 Issue date: November 2017

[©] National Institute for Health and Care Excellence 2017. All rights reserved.